Loading...
NPI 1609491216 · Brooklyn, NY · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Amedix Laboratory is a clinical medical laboratory provider located in Brooklyn, New York. This profile covers 5 Medicare and 5 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Amedix Laboratory |
| Address | 6103 Strickland Ave # Site1 |
| City | Brooklyn |
| State | NY |
| ZIP | 11234 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | June 9, 2020 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $8.9M |
| Medicaid | $237.5K |
AMEDIX LABORATORY’s billing profile is dominated by high-volume molecular infectious-disease testing: the Medicare top code 87636 alone has 58.3K claims, $140 avg paid/claim and $8.2M revenue (92.0% of this provider's total Medicare revenue), and the presence of U0003, U0005 and G2023 on both payers indicates the lab performs high-throughput SARS‑CoV‑2 nucleic acid testing, multiplex respiratory panels (SARS‑CoV‑2/Influenza A/B), and specimen collection services rather than primarily providing routine point-of-care lab work.
Revenue concentration is extreme across both payers: the precomputed top 3 Medicare codes by revenue account for 98.8% of Medicare revenue and the top 3 Medicaid codes by revenue account for 93.1% of Medicaid revenue, indicating the business is highly reliant on a very narrow set of test types and could be sensitive to volume or reimbursement shifts for those specific codes.
The provider is effectively Medicare-dominant in scale: lifetime Medicare revenue is $8.9M compared with $237.5K in Medicaid revenue, so Medicare activity drives the overwhelming share of reported lifetime billing and margin potential while Medicaid represents a comparatively small portion of overall throughput.
AMEDIX is a nationally dominant outlier for code 87636: it ranks #1 of 2192 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code), which positions the lab as an unusually large national supplier of the multiplex SARS‑CoV‑2/Influenza A/B test under Medicare.
Other high-volume COVID-era codes show important but more typical competitive footprints: on Medicare U0003 reports $447.9K revenue (6.1K claims) and ranks #37 of 973 providers (96th percentile; typical, unremarkable volume), and U0005 reports $151.1K (6K claims) and ranks #44 of 1090 (96th percentile; typical, unremarkable volume), indicating strong throughput for high-throughput SARS‑CoV‑2 assays but not the same extreme national concentration as 87636.
Medicaid activity mirrors Medicare test mix but at smaller scale and middling in-state rank: U0003 accounts for $153.1K and 63.9% of Medicaid revenue (3.8K claims) and ranks #120 of 336 in-state (64th percentile; typical, unremarkable volume), while U0005 adds $52.3K (3.7K claims) and 21.8% of Medicaid revenue with an in-state rank of #117 of 297 (61st percentile), together forming the bulk of Medicaid billing consistent with a centralized COVID-testing service.
The provider’s NPI was enumerated on 2020-06-09 (~6 years ago), which aligns with rapid scaling during the COVID era; combined with the large claim counts and code mix (high counts for U0003/U0005 and specimen collection G2023), the operational profile is consistent with a high-throughput laboratory infrastructure focused on centralized infectious-disease testing rather than low-volume local diagnostics.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 58,310 | $140 | $8.2M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 6,050 | $70 | $447.9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 6,040 | $30 | $151.1K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 4,140 | $20 | $95.2K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 280 | $50 | $13.8K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 5 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 3,830 | $40 | $153.1K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 3,740 | $10 | $52.3K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 1,110 | $20 | $17.8K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3,260 | $10 | $16.3K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 20 | $10 | $210 |
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
5 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 120 | 340 | 1,090 | $70 | $1.4M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 117 | 300 | 1,710 | $20 | $458.6K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 34 | 220 | 230 | $70 | $104.3K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 805 | 940 | 220 | $30 | $89.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 71 | 480 | 190 | $10 | $49K |
Other providers in the same ZIP code as Amedix Laboratory, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Americare, Inc. | NY | Home Health Agency | $0 | $686.1M |
| Beth Israel Medical Center | NY | General Acute Care Hospital | $0 | $278.9M |
| I & Y Senior Care, Inc. | NY | Home Health Agency | $0 | $241.8M |
| Americare Certified Special Services, Inc. | NY | Home Health Agency | $0 | $79.4M |
| 24/7 Homecare Agency Of Ny, Inc | NY | Home Health Agency | $0 | $78.7M |
| Americare, Inc. | NY | Home Health Agency | $0 | $64.5M |
| Rishavena Home Health Care Agency Inc. | NY | Home Health Agency | $0 | $30.4M |
| I & Y Senior Care, Inc. | NY | Home Health Agency | $0 | $29.3M |
| Ep Home Care LLC | NY | Home Health Agency | $0 | $22.8M |
| Brook Plaza Ambulatory Surgical Center, Inc. | NY | Ambulatory Surgical Clinic/Center | $3.5M | $5.4M |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.